血浆脑源性 tau 与缺血性脑卒中后功能结局的相关性。
Association of Plasma Brain-Derived Tau With Functional Outcome After Ischemic Stroke.
机构信息
From the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.
出版信息
Neurology. 2024 Feb 27;102(4):e209129. doi: 10.1212/WNL.0000000000209129. Epub 2024 Jan 31.
OBJECTIVES
To investigate whether circulating acute-phase brain-derived tau (BD-tau) is associated with functional outcome after ischemic stroke.
METHODS
Plasma tau was measured by a novel assay that selectively quantifies BD-tau in the (), which includes adult cases with ischemic stroke and controls younger than 70 years, and in an independent cohort of adult cases of all ages (). Associations with unfavorable 3-month functional outcome (modified Rankin scale score >2) were analyzed by logistic regression. Various stratified and sensitivity analyses were performed, for example, by age, stroke severity, recanalization therapy, and etiologic subtype.
RESULTS
This study included 454 and 364 cases from the and 2, with a median age of 58 and 68 years, respectively. Higher acute BD-tau concentrations were significantly associated with increased odds of unfavorable outcome after adjustment for age, sex, day of blood draw, and stroke severity (NIH stroke scale score) in both cohorts (OR per doubling of BD-tau: 2.9 [95% CI 2.2-3.7], = 1 × 10 and 1.8 [1.5-2.2], = 7 × 10, respectively). The association was consistent in the different stratified and sensitivity analyses.
DISCUSSION
BD-tau is a promising blood-based biomarker of ischemic stroke outcomes, and future studies in larger cohorts are warranted.
目的
探讨循环急性期脑源性 tau（BD-tau）是否与缺血性卒中后的功能结局相关。
方法
采用一种新的测定方法测量血浆 tau，该方法选择性地定量测定（）中的 BD-tau，（）中包括缺血性卒中的成年病例和年龄小于 70 岁的对照者，以及另一个年龄较大的成年病例的独立队列（）。通过逻辑回归分析与 3 个月不良功能结局（改良 Rankin 量表评分>2）的相关性。进行了各种分层和敏感性分析，例如按年龄、卒中严重程度、再通治疗和病因亚型进行分析。
结果
本研究纳入了来自队列和队列的 454 例和 364 例病例，中位年龄分别为 58 岁和 68 岁。在两个队列中，在调整年龄、性别、采血日和卒中严重程度（NIH 卒中量表评分）后，较高的急性期 BD-tau 浓度与不良结局的几率增加显著相关（BD-tau 每加倍的比值比：2.9 [95%置信区间 2.2-3.7]，= 1×10；1.8 [1.5-2.2]，= 7×10，分别）。在不同的分层和敏感性分析中，这种相关性都是一致的。
讨论
BD-tau 是缺血性卒中结局的一个很有前途的基于血液的生物标志物，需要在更大的队列中进行进一步研究。
Zotero 插件